Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37870976

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2023 Nov 30
First author
Zhou C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Cancer Discov. 2023 Dec 12;13(12):OF9. doi: 10.1158/2159-8290.CD-ND2023-0012.
    note
    Source null
    related pmid
    37878779
    relationship
    Comment in
  2. citation
    N Engl J Med. 2024 Feb 8;390(6):578-579. doi: 10.1056/NEJMc2314937.
    note
    Source null
    related pmid
    38324502
    relationship
    Comment in
  3. citation
    N Engl J Med. 2024 Feb 8;390(6):579-580. doi: 10.1056/NEJMc2314937.
    note
    Source null
    related pmid
    38324503
    relationship
    Comment in

Authors and identifiers

  1. name
    Zhou C
    type
    Author
  2. name
    Tang KJ
    type
    Author
  3. name
    Cho BC
    type
    Author
  4. name
    Liu B
    type
    Author
  5. name
    Paz-Ares L
    type
    Author
  6. name
    Cheng S
    type
    Author
  7. name
    Kitazono S
    type
    Author
  8. name
    Thiagarajan M
    type
    Author
  9. name
    Goldman JW
    type
    Author
  10. name
    Sabari JK
    type
    Author
  11. name
    Sanborn RE
    type
    Author
  12. name
    Mansfield AS
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Zhou C
    type
    Author
  2. name
    Tang KJ
    type
    Author
  3. name
    Cho BC
    type
    Author
  4. name
    Liu B
    type
    Author
  5. name
    Paz-Ares L
    type
    Author
  6. name
    Cheng S
    type
    Author
  7. name
    Kitazono S
    type
    Author
  8. name
    Thiagarajan M
    type
    Author
  9. name
    Goldman JW
    type
    Author
  10. name
    Sabari JK
    type
    Author
  11. name
    Sanborn RE
    type
    Author
  12. name
    Mansfield AS
    type
    Author
bibliography ids
  1. nci-bib-20c42cbd1112c468f0aa60ef
book metadata
content sha256
59e0070461dda316a2d342c644c7c00a9a42a1335f0f6964260adaf668b827c0
document type
citation
dois
  1. 10.1056/NEJMoa2306441
electronic publication date
display
2023 Oct 21
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:37870976
immutable id
pubmed:37870976@59e0070461dda316a2d342c644c7c00a9a42a1335f0f6964260adaf668b827c0
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
22
name
The New England journal of medicine
nlm unique id
0255562
pages
2039-2051
volume
389
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Cancer Discov. 2023 Dec 12;13(12):OF9. doi: 10.1158/2159-8290.CD-ND2023-0012.
    note
    Source null
    related pmid
    37878779
    relationship
    Comment in
  2. citation
    N Engl J Med. 2024 Feb 8;390(6):578-579. doi: 10.1056/NEJMc2314937.
    note
    Source null
    related pmid
    38324502
    relationship
    Comment in
  3. citation
    N Engl J Med. 2024 Feb 8;390(6):579-580. doi: 10.1056/NEJMc2314937.
    note
    Source null
    related pmid
    38324503
    relationship
    Comment in
outcomes validated
false
pmid
37870976
provenance
batch id
6d213eecf21b6b7867cb
provider
NCBI PubMed ESummary
record sha256
d314a9b71a53d69329a78ffe4134e0e81bf8e1267bf7fe050a4706f4b9d40d97
response sha256
684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
retrieved at
2026-09-09T23:48:19.049083+00:00
publication date
display
2023 Nov 30
precision
day
year
2023
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37870976/
title
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.

Preserved source evidence · Not medical advice